Metotrexate is an immunosuppressor showing a strong similarity with folic acid, used in the pre-transplant and post-transplant protocol for bone marrow transplantation.
Conditioning for bone marrow transplant consisted of high-dose chemotherapy regimens, total body radiotherapy, followed by a short course of metotrexate followed by cyclosporine A in allogeneic bone marrow recipients.
Muti, G., et al. (2000). ‘Incidence and clinical characteristics of posttransplant lymphoproliferative disorders: report from a single center’. Transplant International 13 Suppl 1:S382-7. (RISCEN13)